Design and synthesis of glycofullerene derivatives as novel photosensitizer for potential application in PDT to treat cancer

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL
Xue Bai , Tian Yang , Xinle Shao , Bobo Jia , Huifang Hao , Faiz-Ur Rahman , Yongmin Zhang
{"title":"Design and synthesis of glycofullerene derivatives as novel photosensitizer for potential application in PDT to treat cancer","authors":"Xue Bai ,&nbsp;Tian Yang ,&nbsp;Xinle Shao ,&nbsp;Bobo Jia ,&nbsp;Huifang Hao ,&nbsp;Faiz-Ur Rahman ,&nbsp;Yongmin Zhang","doi":"10.1016/j.ejmech.2024.117009","DOIUrl":null,"url":null,"abstract":"<div><div>Cancer is one of the most aggressive diseases known to humanity, characterized by low survival rates and poor prognoses. Currently, platinum-based anticancer drugs and traditional photosensitizers used in photodynamic therapy (PDT) are the most widely employed treatment modalities. However, the platinum-based medications, particularly cisplatin, the most commonly used agent, have several drawbacks. These drawbacks may include systemic toxicity, which can manifest as nephrotoxicity, neurotoxicity, ototoxicity, or emesis during treatment. Such side effects can severely impair patients and significantly diminish the overall effectiveness of therapeutic interventions. In contrast, photodynamic therapy does not present these disadvantages. PDT offers numerous benefits, including reduced long-term morbidity, minimal systemic toxicity, low invasiveness, negligible drug resistance, and temporal and geographic selectivity, all of which enhance patients' quality of life. Consequently, the search for novel, effective, and practical photosensitizers is essential. Fullerenes possess unique physicochemical properties that make them highly suitable as photosensitizers. In this study, we developed a comprehensive and straightforward synthesis for two water-soluble sugar fullerene derivatives, designated as <strong>12</strong> and <strong>13</strong>. Multiple analytical techniques, including <sup>1</sup>H NMR, <sup>13</sup>C NMR, high-resolution mass spectrometry (HRMS), Fourier-transform infrared spectroscopy (FT-IR), and ultraviolet–visible (UV–Vis) spectroscopy, collectively confirmed the chemical structures of these derivatives and validated their successful synthesis. Upon exposure to white light irradiation at an intensity of 2.5J/cm<sup>2</sup>, compound <strong>13</strong> demonstrated significant biological activity against three distinct tumor cell lines: HepG2, MKN45, and RPMI 4788, with IC<sub>50</sub> values of 5.65 μM, 2.43 μM, and 1.82 μM, respectively. This study establishes a foundation for the development of innovative clinical photosensitizers.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"281 ","pages":"Article 117009"},"PeriodicalIF":6.0000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523424008912","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer is one of the most aggressive diseases known to humanity, characterized by low survival rates and poor prognoses. Currently, platinum-based anticancer drugs and traditional photosensitizers used in photodynamic therapy (PDT) are the most widely employed treatment modalities. However, the platinum-based medications, particularly cisplatin, the most commonly used agent, have several drawbacks. These drawbacks may include systemic toxicity, which can manifest as nephrotoxicity, neurotoxicity, ototoxicity, or emesis during treatment. Such side effects can severely impair patients and significantly diminish the overall effectiveness of therapeutic interventions. In contrast, photodynamic therapy does not present these disadvantages. PDT offers numerous benefits, including reduced long-term morbidity, minimal systemic toxicity, low invasiveness, negligible drug resistance, and temporal and geographic selectivity, all of which enhance patients' quality of life. Consequently, the search for novel, effective, and practical photosensitizers is essential. Fullerenes possess unique physicochemical properties that make them highly suitable as photosensitizers. In this study, we developed a comprehensive and straightforward synthesis for two water-soluble sugar fullerene derivatives, designated as 12 and 13. Multiple analytical techniques, including 1H NMR, 13C NMR, high-resolution mass spectrometry (HRMS), Fourier-transform infrared spectroscopy (FT-IR), and ultraviolet–visible (UV–Vis) spectroscopy, collectively confirmed the chemical structures of these derivatives and validated their successful synthesis. Upon exposure to white light irradiation at an intensity of 2.5J/cm2, compound 13 demonstrated significant biological activity against three distinct tumor cell lines: HepG2, MKN45, and RPMI 4788, with IC50 values of 5.65 μM, 2.43 μM, and 1.82 μM, respectively. This study establishes a foundation for the development of innovative clinical photosensitizers.

Abstract Image

Abstract Image

设计和合成作为新型光敏剂的 Glycofullerene 衍生物,有望应用于治疗癌症的光导疗法
癌症是人类已知的最具侵袭性的疾病之一,其特点是存活率低、预后差。目前,铂类抗癌药物和光动力疗法(PDT)中使用的传统光敏剂是最广泛使用的治疗方式。然而,铂类药物,尤其是最常用的顺铂,存在一些缺点。这些缺点可能包括全身毒性,在治疗过程中可能表现为肾毒性、神经毒性、耳毒性或呕吐。这些副作用会严重损害患者的身体,大大降低治疗干预的整体效果。相比之下,光动力疗法没有这些缺点。光动力疗法有许多优点,包括降低长期发病率、全身毒性极小、低侵入性、耐药性可忽略不计以及时间和地域选择性,所有这些都能提高患者的生活质量。因此,寻找新型、有效和实用的光敏剂至关重要。富勒烯具有独特的物理化学特性,非常适合作为光敏剂。在这项研究中,我们开发了一种全面而简单的方法来合成两种水溶性糖富勒烯衍生物,分别命名为 12 和 13。多种分析技术,包括 1H NMR、13C NMR、高分辨率质谱(HRMS)、傅立叶变换红外光谱(FT-IR)和紫外可见光谱(UV-Vis),共同证实了这些衍生物的化学结构,并验证了它们的成功合成。在强度为 2.5J/cm2 的白光照射下,化合物 13 对三种不同的肿瘤细胞株具有显著的生物活性:其 IC50 值分别为 5.65μM、2.43μM 和 1.82μM。这项研究为开发创新型临床光敏剂奠定了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信